Stocklore

Illumina Inc (ILMN)

Biotech & Health · US stock

Company overview

Illumina. The world's No. 1 in next-generation gene-sequencing equipment. It provides core infrastructure for the precision-medicine and genetic-diagnostics markets.

What is the Biotech & Health sector?

Pharma, biotech, and medical devices. Driven by trial-result events.

Illumina Inc is classified under the Biotech & Health sector. See peers below.

Illumina Inc key financials

Based on SEC filings · latest quarter (TTM)

Tap a metric name to see its meaning in the glossary.

ETFs holding Illumina Inc

Per SEC N-PORT · 2026-04-30 · by weight · factual

ARKKARK Innovation ETF
1.20%
ITOTiShares Core S&P Total U.S. Stock Market ETF
0.03%
VTIVANGUARD TOTAL STOCK MARKET INDEX FUND
0.03%

ILMN on Stocklore

  • Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
  • Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
  • 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
  • Sector-relative metrics — valuation and growth vs the Biotech & Health average
See full ILMN analysis →

Peers · Biotech & Health

ILMN FAQ

What is Illumina Inc (ILMN)?

Illumina. The world's No. 1 in next-generation gene-sequencing equipment. It provides core infrastructure for the precision-medicine and genetic-diagnostics markets.

What sector is Illumina Inc in?

Illumina Inc is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.

What are Illumina Inc's key financials?

Based on the latest quarter (TTM) from SEC filings: Revenue growth (YoY) 1.3%, Operating margin 19.2%, Net margin 19.4%, ROE 31.2%. Definitions and interpretation are available on Stocklore.

Where can I analyze Illumina Inc (ILMN) stock?

On Stocklore you can see ILMN's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.

Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, 45-day delay), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.

Not an investment adviser and not personalized investment advice; not a discretionary management service. No trade recommendations, no target prices, no execution or brokerage. We do not recommend or guarantee any purchase, sale, or returns. Investment decisions and their outcomes are your own.

Stocklore · CEO Lee Seung-jae · Business reg. no. 764-36-01607 · E-commerce permit 2026-Jeonju Wansan-0476 · Tel +82-70-7954-4939 · S120, Rm 302, 3F, 21 Jungsanjungang-ro, Wansan-gu, Jeonju, Jeonbuk, Korea